UK Healthtech Startup Nul Secures $1M Seed Round Led by Dmg Ventures and BYVP

Why It Matters

Nul’s evidence‑based, subscription‑based model tackles a massive, underserved segment of healthcare, promising scalable, discreet treatment for harmful drinking. Its success could spur broader digital innovation in addiction care and attract further capital to the space.

Key Takeaways

• Nul raised $1M seed led by dmg ventures
• Platform combines telehealth, naltrexone, and behavioral support
• Over £300k ARR achieved with 120+ customers
• Focuses on reduction, not mandatory abstinence
• Plans UK launch, US expansion, and crowdfunding

Pulse Analysis

Alcohol use disorder remains a global health crisis, yet treatment innovation has lagged behind other chronic conditions. Recent telehealth breakthroughs have reshaped weight‑loss and mental‑health services, demonstrating that digital delivery can lower barriers and improve adherence. Nul’s entry into this space aligns with a broader industry shift toward remote, medication‑assisted therapies, positioning it to capture demand from consumers seeking discreet, flexible solutions.

Nul’s platform leverages the Sinclair Method, pairing prescription naltrexone with structured digital guidance to reduce cravings without demanding total abstinence. By offering virtual clinician visits, ongoing support, and a subscription model, the startup creates a continuous care loop that mirrors successful SaaS health products. Early traction—over £300,000 annualised revenue from 120+ users—signals strong organic demand and validates the market appetite for evidence‑based, reduction‑focused treatment pathways.

The $1 million seed round not only finances a nationwide UK rollout but also fuels product development, regulatory navigation, and a planned US expansion. As investors increasingly target health‑tech solutions that combine pharma and software, Nul’s model could attract further capital and inspire competitors to modernise addiction care. Successful scaling may also influence policy, encouraging insurers and public health systems to reimburse digital alcohol‑reduction programs, thereby expanding access and reducing societal costs associated with harmful drinking.

Deal Summary

Nul, a UK‑based healthtech startup focused on alcohol reduction, announced a $1 million seed funding round. The round was led by dmg ventures and BYVP, with participation from a group of angel investors, and will fund the company’s UK commercial launch and international expansion plans.